Ann: Positive Disc Repair Results Using Mesoblast, page-24

re: Ann: Positive Disc Repair Results Using M... The shorts are interesting and not completely foolish, this is a highly volatile stock that has traded through a range for the past year. So at the moment they are making money, which is what they are paid to do. This is great until they get caught out with positive Ph III or advanced approval, in which case they will be scrambling to cover!

I haven't read the Macq report but am extremely interested in the methodology he uses to arrive at his valuation. With most of the competitors (if not all) using a probability weighted DCF, which is the norm in biotechs he must assign either a 20-30% probability or suggest the addressable markets are much smaller than what is being suggested. I think it's always interesting that contrarian analysts will do well occasionally yet their opinion gets traction as people are worried about the downside to holding something like this.

Remember this is potentially a paradigm shift in the treatment of many diseases that ail a huge proportion of our growing ageing population. With great risk comes great reward and if this gets down to the bottom of the range I will potentially scrape together what I can to buy more!